{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '7.1', 'INCLUSION CRITERIA', '41', '7.2', 'EXCLUSION CRITERIA', '41', '7.2.1', 'Exclusion criteria related to study methodology', '41', '7.2.2', 'Exclusion criteria related to alemtuzumab and/or mandatory background therapies', '42', '7.2.3', 'Exclusion criteria related to the current knowledge of alemtuzumab and study methodology', '43', '8', 'STUDY TREATMENTS', '46', '8.1', 'INVESTIGATIONAL MEDICINAL PRODUCT(S)', '46', '8.1.1', 'Administration', '46', '8.1.1.1', 'Method of preparation at the clinical site', '47', '8.1.1.2', 'Special precautions for disposal and other handling', '47', '8.2', 'NONINVESTIGATIONAL MEDICINAL PRODUCTS', '47', '8.3', 'BLINDING PROCEDURES', '48', '8.3.1', 'Methods of blinding', '48', '8.4', 'METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUP', '49', '8.5', 'PACKAGING AND LABELING', '49', '8.6', 'STORAGE CONDITIONS AND SHELF LIFE', '49', '8.7', 'RESPONSIBILITIES', '49', '8.7.1', 'Treatment accountability and compliance', '50', '8.7.2', 'Return and/or destruction of treatments', '50', '8.8', 'CONCOMITANT MEDICATION', '50', '9', 'ASSESSMENT OF INVESTIGATIONAL MEDICINAL PRODUCT', '53', '9.1', 'PRIMARY ENDPOINT', '53', '9.1.1', 'Primary efficacy endpoint', '53', '9.1.1.1', 'Brain MRI', '53', '9.2', 'SECONDARY ENDPOINTS', '54', '9.2.1', 'Secondary efficacy endpoints', '54', '9.2.1.1', 'Expanded disability status scale', '54', '9.2.1.2', 'Annualized relapse rate at Year 2', '55', '9.2.1.3', 'Cognition test scores', '55', '9.2.2', 'Other secondary endpoints', '56', '9.2.2.1 Pharmacokinetics', '56', '9.2.2.2', 'Pharmacodynamic variables', '57', '9.2.2.3', 'Quality of life endpoints', '57', '9.3', 'SAFETY ENDPOINTS', '58', 'Property of the Sanofi Group - strictly confidential', 'Page 23', 'VV-CLIN-02544065.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '9.3.1', 'Adverse events', '59', '9.3.2', 'Laboratory safety variables', '59', '9.3.3', 'ITP, cytopenia, and antiGBM surveillance and monitoring', '60', '9.3.4', 'Hemophagocytic lymphohistiocytosis', '61', '9.3.5', 'Physical examination and vital signs', '61', '9.3.6', 'Other safety endpoints', '62', '9.4', 'EXPLORATORY ENDPOINT', '62', '9.5', 'FUTURE USE OF SAMPLES', '62', '9.5.1', 'Immune markers (optional)', '62', '9.6', 'APPROPRIATENESS OF MEASUREMENTS', '62', '10', 'STUDY PROCEDURES', '64', '10.1', 'VISIT SCHEDULE', '64', '10.1.1', 'Visit 1 Screening visit', '64', '10.1.2', 'Visit 2/( M-4) study eligibility confirmation visit', '65', '10.1.3', 'Visit 3/Days - 14 to -7', '66', '10.1.4', 'Visit 4/M0/D1 (first course of alemtuzumab)', '66', '10.1.5', 'Visit 5 to Visit 7/M1 to M3', '68', '10.1.6', 'Visit 8/M4', '69', '10.1.7', 'Visit 9 to Visit 11 /M5 to M7', '69', '10.1.8', 'Visit 12/M8', '69', '10.1.9', 'Visit 13 to Visit 15/M9 to M11', '70', '10.1.10', 'Visit 16/M12 (second course of alemtuzumab)', '70', '10.1.11', 'Visit 17 to Visit 18/M13 to M14', '72', '10.1.12', 'Visit 19/M15', '72', '10.1.13', 'Visit 20 to Visit 21/M16 to 17', '73', '10.1.14', 'Visit 22/M18', '73', '10.1.15', 'Visit 23 to Visit 24/M19 to M20', '73', '10.1.16', 'Visit 25/M21', '73', '10.1.17', 'Visit 26-Visit 27/M22-23', '74', '10.1.18', 'Visit 28/M24 EOTP', '74', '10.1.19 Safety monitoring phase Year 3 to Year 5', '74', '10.1.20', 'Relapse Visit', '75', '10.2', 'DEFINITION OF SOURCE DATA', '75', '10.3', 'HANDLING OF PATIENT TEMPORARY OR PERMANENT TREATMENT', 'DISCONTINUATION AND OF PATIENT STUDY DISCONTINUATION', '75', 'Property of the Sanofi Group - strictly confidential', 'Page 24', 'VV-CLIN-0254406 5.0']\n\n###\n\n", "completion": "END"}